Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies Reply

被引：1
|
作者：
Spencer, Andrew [1 ]
Prince, H. Miles [2 ]
Roberts, Andrew W. [3 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 32期
关键词：
CONSOLIDATION THERAPY; SURVIVAL;
D O I：
10.1200/JCO.2009.24.0853
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E188 / E188
页数：1
相关论文
共 50 条
  • [21] Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma
    Minarik, J.
    Scudla, V.
    Bacovsky, J.
    Zemanova, M.
    Pika, T.
    Ordeltova, M.
    Langova, K.
    NEOPLASMA, 2010, 57 (01) : 8 - 14
  • [22] Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
    Mian, Michael
    Tinelli, Martina
    De March, Elena
    Turri, Gloria
    Meneghini, Vittorio
    Pescosta, Norbert
    Berno, Tamara
    Marabese, Alessandra
    Mondello, Patrizia
    Patriarca, Francesca
    Pizzolo, Giovanni
    Semenzato, Gianpietro
    Cortelazzo, Sergio
    Zambello, Renato
    ANTICANCER RESEARCH, 2016, 36 (03) : 1059 - 1065
  • [23] Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma
    Offidani, Massimo
    Corvatta, Laura
    Polloni, Claudia
    Gentili, Silvia
    Mele, Anna
    Rizzi, Rita
    Catarini, Massimo
    Caraffa, Patrizia
    Samori, Arduino
    Blasi, Nicola
    Ferranti, Mario
    Malerba, Lara
    Brunori, Marino
    Leoni, Pietro
    ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1449 - 1456
  • [24] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [25] Carfilzomib for relapsed or refractory multiple myeloma reply
    Dimopoulos, Meletios A.
    Kimball, Amy S.
    LANCET ONCOLOGY, 2018, 19 (01) : E2 - E2
  • [26] Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications
    Minuk, L.
    Sibbald, R.
    Peng, J.
    Bejaimal, S.
    Chin-Yee, I.
    CURRENT ONCOLOGY, 2010, 17 (04) : 145 - 153
  • [27] The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
    Ho Sup Lee
    Chang-Ki Min
    Je-Jung Lee
    Kihyun Kim
    Seok Jin Kim
    Dok Hyun Yoon
    Hyeon-Seok Eom
    Hyewon Lee
    Won Sik Lee
    Ho-Jin Shin
    Ji Hyun Lee
    Yong Park
    Jae-Cheol Jo
    Young Rok Do
    Yeung-Chul Mun
    Mark Hong Lee
    Annals of Hematology, 2016, 95 : 911 - 919
  • [28] The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je-Jung
    Kim, Kihyun
    Kim, Seok Jin
    Yoon, Dok Hyun
    Eom, Hyeon-Seok
    Lee, Hyewon
    Lee, Won Sik
    Shin, Ho-Jin
    Lee, Ji Hyun
    Park, Yong
    Jo, Jae-Cheol
    Do, Young Rok
    Mun, Yeung-Chul
    Lee, Mark Hong
    ANNALS OF HEMATOLOGY, 2016, 95 (06) : 911 - 919
  • [29] Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma
    Kapoor, P.
    Kumar, S.
    Mandrekar, S. J.
    Laumann, K. M.
    Dispenzieri, A.
    Lacy, M. Q.
    Dingli, D.
    Gertz, M. A.
    Kyle, R. A.
    Greipp, P. R.
    Rajkumar, S. V.
    Witzig, T. E.
    LEUKEMIA, 2011, 25 (07) : 1195 - 1197
  • [30] Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gutierrez, Norma
    Teruel, Ana-Isabel
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz Mediavilla, Joaquin
    Palomera, Luis
    de Arriba, Felipe
    Gonzalez, Yolanda
    Hernandez, Jose-Mariano
    Sureda, Ana
    Bello, Jose-Luis
    Bargay, Joan
    Penalver, Francisco-Javier
    Ribera, Jose-Maria
    Martin-Mateos, Maria-Luisa
    Garcia-Sanz, Ramon
    Cibeira, Maria-Teresa
    Martin Ramos, Maria-Luisa
    Vidriales, Maria-Belen
    Paiva, Bruno
    Montalban, Maria-Angeles
    Lahuerta, Juan-Jose
    Blade, Joan
    San Miguel, Jesus-Fernando
    LANCET ONCOLOGY, 2010, 11 (10) : 934 - 941
12345